In a case report published in the World Journal of Oncology, an elderly female patient was diagnosed with mast cell leukemia (MCL), with imaging showing extensive osteoblastic metastatic lesions. MCL ...

In a real-world study, researchers found this data by comparing treatment patterns, healthcare resource utilization, and ...

So I touched on that a minute ago when I was talking about p53 mutated, and should we say a highly aggressive, multiply relapsed, or all types of mantle cell lymphoma that can be a lot more ...

They're both slow-growing, and you treat them the same way. The only difference is where these cancers start: Mantle cell lymphoma (MCL) is a rare and fast-growing cancer. About 6% of all non ...

Bristol Myers Squibb gets European Commission approval to expand use of CAR T cell therapy, Breyanzi for relapsed or refractory follicular lymphoma: Princeton, New Jersey Monday, ...

Gilead Sciences’ Kite Pharma unit is closing on approval of its second European approval for a CAR-T for cancer, after the CHMP backed its KTE-X19 therapy for mantle cell lymphoma.

DelveInsight's 'BREYANZI Market Size, Forecast, and Market Insight Report' highlights the details around BREYANZI, a CD19-directed CAR T-cell therapy with a 4-1BB co-stimulatory domain, which enhances ...